AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05144217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3x 280 mg per day
Description: 3 capsule per day of silimarit
Study NCT05144217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1x 1120 mg
Description: 8 capsule per day of silimarit
Study NCT05966207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Stimulation
Description: The Individual Cognitive Stimulation will be conducted by caregivers, with support by the research team. The intervention will span 12 weeks, consisting of three weekly sessions (30 minutes each session), totaling 36 sessions. Caregivers in this study will utilize a previously translated and validated version of Making a Difference 3 - Individual Intervention of Cognitive Stimulation - A manual for caregivers, specifically adapted for the European Portuguese population.
Study NCT04718649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex with Joins or not
Description: The enrolled patienst will be divided into the group taking celecoxib 200mg with Joins tab together and the group taking celecoxib 200mg with Joins placebo in the same probability of 2:1 according to the randomization table at the first outpatient visit. Among the co-researchers, one researcher who is in charge of patient assignment will create a randomization table through computer generated randomization. And this researcher who is charge of the patient assignment will not intervene in any other process of this study, and only participates in the task of selecting the assigned group using random checks. The evaluation will be evaluated by an researcher who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study
Study NCT04718649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celebrex with Joins or not
Description: The enrolled patienst will be divided into the group taking celecoxib 200mg with Joins tab together and the group taking celecoxib 200mg with Joins placebo in the same probability of 2:1 according to the randomization table at the first outpatient visit. Among the co-researchers, one researcher who is in charge of patient assignment will create a randomization table through computer generated randomization. And this researcher who is charge of the patient assignment will not intervene in any other process of this study, and only participates in the task of selecting the assigned group using random checks. The evaluation will be evaluated by an researcher who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study
Study NCT04802551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory integration therapy
Description: Sensory integration disorder is defined as the inability of a person to use the information he / she receives through his / her senses properly in order to continue his daily life properly. Intervention group have some therapy sessions which include sensory integration therapy exercises.
Study NCT05877638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel
Description: (FDA) 510(k) cleared wound care medical devices formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn serves as a protective gel dressing.
Study NCT05877638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SILVADENE Cream 1% (silver sulfadiazine)
Description: SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
Study NCT04707794 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane delivery will will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
Study NCT04707794 — intervention group
Intervention type: DRUG
Intervention: Desflurane
Description: Desflurane delivery will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
Study NCT06120751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTVA
Description: Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
Study NCT06120751 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TT
Description: Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
Study NCT04650893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ketorolac
Description: To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
Study NCT04650893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Dexamethasone
Description: To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
Study NCT04650893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control
Study NCT05510934 — intervention group
Intervention type: BEHAVIORAL
Intervention: Shared-care model
Description: A Shared care follow-up strategy involving patients, PCPs and specialists that uses an automated reminder system (TCARS).
Study NCT04933422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM93
Description: oral capsule of CM93 administered once daily
Study NCT05027789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided
Description: People in this arm will come to 15 information sessions. These sessions will provide training and education on memory support strategies and healthy lifestyles. You will decide how you want to implement this information into your daily life.
Study NCT04230694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom Generation 6 CGM (Dexcom Gen6) device
Description: Standing orders for blood sugars less than 100 will allow for administration of glucose replacement in the intervention group based on Dexcom Gen6 readings.
Study NCT05027789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Group
Description: People in this group will come to 15 information sessions. The study will provide recommended behavior targets (like how much exercise you should have each week). Participants in this group will either receive an iPad or have a special application installed on their own personal device. They will receive training on how to use the application, and will be asked to use the application to record their activities and receive reminders.
Study NCT04230694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom Generation 6 CGM (Dexcom Gen6) device
Description: Standing orders for blood sugars less than 100 will allow for administration of glucose replacement in the intervention group based on Dexcom Gen6 readings.
Study NCT05440188 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Detect Platform
Description: Use of the Breath Detect platform for respiratory health monitoring.
Study NCT06327659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30 mL syringe manual thrombectomy catheter
Description: 30 mL syringe manual thrombectomy catheter
Study NCT06327659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 50 mL syringe manual thrombectomy catheter
Description: 50 mL syringe manual thrombectomy catheter
Study NCT04964843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine is an FDA approved medication that is used to treat acetaminophen overdose.
Study NCT04964843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05030246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib/Toripalimab
Description: Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
Study NCT05988489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Deconstructive Psychotherapy (DDP)
Description: DDP treatment with an assigned therapist for up to 12 months
Study NCT05988489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention and Contact (BIC)
Description: BIC treatment with an assigned therapist for up to 12 months
Study NCT05931198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified illusion of the rubber (syncrhone)
Description: The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis at the same time (synchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
Study NCT05931198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified illusion of the rubber (asynchrone)
Description: The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis not at the same time (asynchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
Study NCT05743881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection
Study NCT05743881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1365
Description: Sterile liquid for injection
Study NCT05743881 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) solution for injection
Study NCT05743881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nimenrix
Description: Solution for injection
Study NCT05541497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate
Description: Days 1-3: 0.5mg study pill once per day, Days 4-7: 0.5mg study pill twice per day, Weeks 2-8: 1mg study pill twice per day
Study NCT05541497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day
Study NCT06138587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine Induced Memory-like Natural Killer Cells
Description: Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
Study NCT06138587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.
Study NCT05049031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: A questionnaire will be given to patients who will ask them about their possible fractures, their bone and oncological follow-ups and their possible cardiovascular events since the end of treatment with hormone therapy.
Study NCT05504824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case-based education
Description: The education phase This stage included the explanation of the CR process, the analysis of CR cases, the drafting of new cases suitable for the CR process by students, and the analysis process.~The education program was carried out on a web platform (Zoom) consistent with the changes in the COVID-19 pandemic process. The CR cases to be used in case-based education were sent to the students via e-mail before the group interview to make sure students came prepared for the group discussion. In case-based education, after the students read the case, they were asked some questions to determine their decisions and reasoning.
Study NCT06396637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride
Description: Sapropterin Dihydrochloride: 20mg/kg, qd
Study NCT04950686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Aware for Young Adults
Description: Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults that uses a media literacy education (MLE) approach.
Study NCT04950686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Aware for Young Adults
Description: Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults.
Study NCT06435312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Zilucoplan will be administered subcutaneously to pediatric study participants
Study NCT04604782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR
Study NCT05058352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS269
Description: Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.
Study NCT04940208 — intervention group
Intervention type: OTHER
Intervention: Pain and neuropsychological questionnaires
Description: Patient-reported outcomes, listed in the Secondary Outcome Measure Section
Study NCT04940208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory testing
Description: Summation pain threshold test and Heat pain threshold skin test
Study NCT06191523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group will receive standard therapy and placebo.
Study NCT06191523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group will receive standard therapy and placebo.
Study NCT06191523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Group
Description: The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
Study NCT06191523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Group
Description: The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
Study NCT06028841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1553
Description: Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
Study NCT06507969 — intervention group
Intervention type: OTHER
Intervention: The Effect of Body Composition on Respiratory Parameters, Functional Capacity and Sleep in Healthy Young Adults
Description: Sociodemographic information of all participants will be obtained within the scope of the evaluations. Body composition parameters will be measured with Tanita DC360 Body Analysis Scale. In pulmonary function test, Forced vital capacity (FVC), Forced expiratory volume in 1st second (FEV1), Tiffeneau ratio (FEV1/FVC), peak expiratory flow rate (PEF) values will be evaluated with COSMED Pony FX (COSMED; Italy) spirometer. Respiratory muscle endurance will be assessed by Maximum Minute Ventilation will be determined. Pittsburg Sleep Quality, a reliable questionnaire that assesses sleep quality The index will be filled in by the participants. 6 Minutes to assess functional capacity A walking test will be performed and the distance travelled by individuals will be recorded
Study NCT05120596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab+T3P-Y058-739
Description: intravenous infusion or intratumoural injection
Study NCT05120596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3P-Y058-739 (IV)
Description: Intravenous infusion
Study NCT05120596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3P-Y058-739 (IT)
Description: Intratumoral use
Study NCT05202379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: CC-42344 capsules
Study NCT05202379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules
Study NCT06212921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sequential blood samples
Description: Sequential blood samples for diagnostic tests is the only intervention in thei study
Study NCT05650411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMCA PCI with Biofreedom Ultra drug-coated stent (Biosensors International, Switzerland)
Description: Successful LMCA PCI with ≥1 BioFreedom Ultra polymer-free drug-coated stent (Biosensors International, Switzerland).
Study NCT05650411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMCA PCI with Biofreedom Ultra drug-coated stent (Biosensors International, Switzerland)
Description: Successful LMCA PCI with ≥1 BioFreedom Ultra polymer-free drug-coated stent (Biosensors International, Switzerland).
Study NCT05650411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor-based SAPT after short DAPT
Description: Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.
Study NCT05650411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional DAPT
Description: 6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.
Study NCT06253052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional pre-OP-visit
Description: OP-schedule is closely monitored and patients will be visited to support and encourage them in drinking clear fluids.
Study NCT06253052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional pre-OP-visit
Description: OP-schedule is closely monitored and patients will be visited to support and encourage them in drinking clear fluids.
Study NCT06253052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liberal fasting regime
Description: Patients may drink up to 200 ml clear fluids between 2 h prior to the surgery and the call to operation room.
Study NCT06189716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow oxygen through nasal cannula
Description: High flow oxygen through nasal cannula and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions.
Study NCT05300555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
Study NCT05300555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
Study NCT05116007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion
Study NCT05116007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT05116007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
Study NCT05285644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR 15512 Ophthalmic Solution
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Study NCT05285644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Study NCT05304208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesopher
Description: autologous monocyte-derived DCs loaded with PheraLys (tumor cell lysate)
Study NCT04407611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online modality
Description: Return of BRCA results directly online or return of printed BRCA results if participant cannot access online or chooses not to
Study NCT04407611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic counselor follow-up
Description: Optional genetic counselor follow-up over the telephone
Study NCT06680999 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Preoperative, intraoperative and follow-up data collection: consultation and anesthesia reports, hospitalization reports and imaging data to evaluate the feasibility and efficacy of endovascular treatment of superior vena cava syndromes involving the trifurcation. Data collection will last 1 month and will be performed by a Vascular Surgery resident of the hospital.
Study NCT06680115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine